Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 17/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25168550 | 0.87 | OPRD1 (0.66) | CHRM2CHRM1OPRD1OPRM1CYP2D6 | |
| SCHEMBL25168549 | 0.87 | OPRD1 (0.66) | CHRM2CHRM1OPRD1OPRM1CYP2D6 | |
| SCHEMBL13380743 | 0.86 | OPRD1 (0.65) | CHRM2CHRM1OPRD1OPRM1CYP2D6 | |
| Hydrochloric Acid SCHEMBL4417655 | 0.84 | CHRM2 (0.52) | CHRM2CHRM1OPRD1OPRM1CYP2D6 | |
| SCHEMBL26199219 | 0.83 | OPRD1 (0.69) | CHRM2CHRM1OPRD1OPRM1 | |
| SCHEMBL1978575 | 0.83 | OPRD1 (0.69) | CHRM2CHRM1OPRD1OPRM1 | |
| SCHEMBL5915113 | 0.80 | CHRM2 (0.56) | CHRM2CHRM1OPRD1OPRM1CYP2D6 | |
| SCHEMBL20883792 | 0.79 | CHRM2 (0.59) | CHRM2CHRM1OPRD1CYP2D6CYP19A1 | |
| SCHEMBL15318609 | 0.78 | CHRM2 (0.58) | CHRM2CHRM1OPRD1OPRM1CYP2D6 | |
| SCHEMBL2264950 | 0.76 | CHRM2 (0.56) | CHRM2CHRM1OPRD1OPRM1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | disclosed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | FLT1, FLT4, VEGFA | CHRM2 1350/4885CHRM1 973/4885OPRD1 1542/4885 |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | CHRM2 664/4885CHRM1 492/4885OPRD1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.